This study assessed the safety and immunogenicity of motavizumab, an investigational anti-RSV MAb, in young children with a history of prematurity who received two sequential seasons of the antibody.
RSV Surveillance: Retrospective and Current Data on the Variance in Season Onsets and Offsets (Poster Presentation #719) Jessie R. Groothuis M.D., MedImmune, Saturday, October 6, 2007; 12:15 1:45 p.m. in Poster Halls G-H.
A nationwide active surveillance program was established to evaluate the variability of the RSV season temporally and geographically in the United States. Laboratory results from a three-year period were analyzed by month and by geographic region.
'/>"/>
| Contact: Tor Constantino constantinos@medimmune.com 301-398-5801 Edelman Public Relations Source:Eurekalert |